Preclinical anticancer activity of DNA-based cleavage molecules

Drug Development and Industrial Pharmacy

Volumn 32, Issue 1, 2006, Pages 1-5

  Dass, Crispin R ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

Anticancer; Cancer; DNAzyme; Gene therapy; Oligonucleotide

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; ANTISENSE OLIGONUCLEOTIDE; BCR ABL PROTEIN; COMPLEMENTARY RNA; CYCLODEXTRIN; DENDRIMER; DEOXYRIBOZYME; DNA; DRUG CARRIER; DZ 13; DZ IV; DZ TWT; EARLY GROWTH RESPONSE FACTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR; FOMIVIRSEN; LIPID; LIPOSOME; ORNITHINE DECARBOXYLASE; PHOSPHOROTHIOIC ACID DERIVATIVE; PORPHYRIN DERIVATIVE; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR TWIST; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER; CANCER MODEL; CELL BASED GENE THERAPY; CELL CULTURE; CELLULAR DISTRIBUTION; CYTOMEGALOVIRUS INFECTION; DRUG ACTIVITY; DRUG DESIGN; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SCREENING; DRUG STABILITY; DRUG TARGETING; ENZYMATIC DEGRADATION; ENZYME MODIFICATION; ENZYME STABILITY; EYE INFECTION; GENE DELIVERY SYSTEM; GENE TARGETING; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; ONCOGENE C MYC; RNA DEGRADATION; VIRAL GENE THERAPY; WART VIRUS;

ANIMALS; CELLS, CULTURED; DNA, CATALYTIC; DNA, SINGLE-STRANDED; GENES, JUN; HUMANS; NEOPLASMS; ORNITHINE DECARBOXYLASE; TWIST TRANSCRIPTION FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 32344450506     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040500387872     Document Type: Article

References (30)

1. Ackermann, J. M., Kanugula, S., & Pegg, A. E. (2005). DNAzyme-mediated silencing of ornithine decarboxylase. Biochemistry, 44, 2143-2152.
2. Arora, V., Devi, G. R., & Iversen, P. L. (2004). Neutrally charged phosphorodiamidate morpholino antisense oligomers: uptake, efficacy, and pharmacokinetics. Curr. Pharm. Biotechnol., 5, 431-439.
3. Arteaga, C. L., & Baselga, J. (2003). Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: implications for drug development and practice. Clin Cancer Res, 9, 1579-1589.
4. Beale, G., Hollins, A. J., Benboubetra, M., Sohail, M., Fox, S. P., Benter, I., & Akhtar, S. (2003). Gene silencing nucleic acids designed by scanning arrays: anti-EGFR activity of siRNA, ribozyme, and DNA enzymes targeting a single hybridization-accessible region using the same delivery system. J Drug Target, 11, 449-456.
5. Breaker, R. R. (2004). Natural and engineered nucleic acids as tools to explore biology. Nature, 432, 838-845.
6. Cairns, M. J., Hopkins, T. M., Witherington, C., Wang, L., & Sun, L. Q. (1999). Target site selection for an RNA-cleaving catalytic DNA. Nat. Biotech., 17, 480-486.
7. Cieslak, M., Niewiarowska, J., Nawrot, M., Koziolkiewicz, M., Stec, W. J., & Cierniewski, C. S. (2002). DNAzymes to β1 and β3 mRNA down-regulate expression of the targeted integrins and inhibit endothelial cell capillary tube formation in fibrin and matrigel. J. Biol. Chem., 277, 6779-6787.
8. Dass, C. R. (2002). Liposome-mediated delivery of oligodeoxynucleotides in vivo. Drug Deliv, 9, 169-180.
9. Dass, C. R. (2004a). Deoxyribozymes: cleaving a path to clinical trials. Trends Pharmacol. Sci., 25, 395-397.
10. Dass, C. R. (2004b). Tumour angiogenesis, vascular biology, and enhanced drug delivery. J. Drug Target., 12, 245-255.
11. Dass, C. R., Saravolac, E. G., Li, Y., & Sun, L. Q. (2002). Cellular uptake, distribution, and stability of 10-23 deoxyribozymes. Antisense Nucleic Acid Drug Dev, 12, 289-299.
12. Fahmy, R. G., Dass, C. R., Sun, L. Q., Chesterman, C. N., & Khachigian, L. M. (2003). Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth. Nat. Med., 9, 1026-1032.
13. Hjiantoniou, E., Iseki, S., Uney, J. B., & Phylactou, L. A. (2003). DNAzyme-mediated deavage of Twist transcripts and increase in cellular apoptosis. Biochem. Biophys. Res. Commun., 300, 178-181.
14. Holmlund, J. T. (2003). Applying antisense technology. Ann. NY Acad. Sci., 1002, 244-251.
15. Khachigian, L. M., Fahmy, R. G., Zhang, G., Bobryshev, Y. V., & Kaniaros, A. (2002). c-Jun regulates vascular smooth muscle cell growth and neointima formation after arterial injury. Inhibition by a novel DNA enzyme targeting c-Jun. J. Biol. Chem., 277, 22985-22991.
16. Lowe, H. C., Chesterman, C. N., & Khachigian, L. M. (2002). Catalytic antisense DNA molecules targeting Egr-1 inhibit neointima formation following permanent ligation of rat common carotid arteries. Thromb. Haemost., 87, 134-140.
17. Lowe, H. C., Fahmy, R. G., Kavurma, M. M., Baker, A., Chesterman, C. N., & Khachigian, L. M. (2001). Catalytic oligodeoxynucleotides define a key regulatory role for early growth response factor-1 in the porcine model of coronary in-stent restenosis. Circ. Res., 89, 670-677.
18. Mitchell, A., Dass, C. R., Sun, L. Q., & Khachigian, L. M. (2004). Inhibition of human breast carcinoma proliferation, migration, chemoinvasion, and solid tumour growth by DNAzymes targeting the zinc finger transcription factor EGR-1. Nucleic Acids Res, 32, 3065-3069.
19. O'Neill, J, Manion, M, Schwartz, P, & Hockenbery, D. M. (2004). Promises and challenges of targeting Bcl-2 anti-apoptotic proteins for cancer therapy. Biochim. Biophys. Acta., 1705, 43-51.
20. Reese, C. B., & Yan, H. B. (2002). Solution phase synthesis of ISIS 2922 (Vitravene) by the modified H-phosphonate approach. J. Chem. Soc. Perkins Trans., 1, 2619-2626.
21. Santiago, F. S., Kavurma, M. M., Lowe, H. C., Chesterman, C. N., Baker, A., Atkins, D. G., & Khachigian, L. M. (1999). New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury. Nat. Med., 5, 1264-1269.
22. Santoro, S. W., & Joyce, G. F. (1997). A general purpose RNA-cleaving DNA enzyme. Proc. Natl. Acad. Sci. U.S.A., 94, 4262-4266.
23. Singhal, N., Bapsy, P. P., Babu, K. G., & George, J. (2004). Chronic myeloid leukemia. J. Assoc. Physicians India., 52, 410-416.
24. Sioud, M., & Leirdal, M. (2000). Design of nuclease resistant protein kinase c α DNA enzymes with potential therapeutic application. J. Mol. Biol., 296, 937-947.
25. Subhi, A. L., Tang, B., Balsara, B. R., Altomare, D. A., Testa, J. R., Cooper, H. S., Hoffman, J. P., Meropol, N. J., & Kruger, W. D. (2004). Loss of methylthioadenosine phosphorylase and elevated ornithine decarboxylase is common in pancreatic cancer. Clin Cancer Res, 10, 7290-7296.
26. Sun, L. Q., Cairns, M. J., Gerlach, W. L., Witherington, C., Wang, L., & King, A. (1999). Suppression of smooth muscle cell proliferation by a c-myc RNA-cleaving deoxyribozyme. J. Biol. Chem., 274, 17236-17241.
27. Wu, Y., Yu, L., McMahon, R., Rossi, J. J., Forman, S. J., & Snyder, D. S. (1999). Inhibition of bcr-abl oncogene expression by novel deoxyribozymes (DNAzymes). Hum. Gene. Ther., 10, 2847-2857.
28. Yang, J., Mani, S. A., Donaher, J. L., Ramaswamy, S., Itzykson, R. A., Come, C., Savagner, P., Gitelman, I., Richardson, A., & Weinberg, R. A. (2004). Twist, a master regulator of morphogenesis, plays an essentia role in tumor metastasis. Cell, 117, 927-939.
29. Zhang, G., Dass, C. R., Sumithran, E., Di Girolamo, N., Sun, L. Q., & Khachigian, L. M. (2004). Effect of deoxyribozymes targeting c-Jun on solid tumor growth and angiogenesis in rodents. J Natl Cancer Inst, 96, 683-696.
30. Zhang, L., Gasper, W. J., Stass, S. A., Ioffe, O. B., Davis, M. A., & Mixson, A. J. (2002). Angiogenic inhibition mediated by a DNAzyme that targets vascular endothelial growth factor receptor 2. Cancer Res, 62, 5463-5469.